AI-powered drug discovery startup Numerate collaborates on French pharmaceutical company Servier's ryanodine receptor work

June 05, 2018 | Case Study

Servier is a pharmaceutical company focused on cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, neurodegenerative diseases, and generic drugs. Of that list, the company's primary source of revenue comes from cardiovascular diseases, and Servier is investing about 25% of its $5 billion revenue back into R&D for future drug development, in areas like heart failure in particular. As such, any improvements to this R&D process – whether it is on new dosage combinations or new molecular entities – has a large established base upon which to make a difference. The help drive such improvements, Servier partnered with Numerate, a startup that uses machine learning to design drug-like molecules for hard-to-target diseases.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978